Activaero appoints chief business officer
Christian Pangratz takes the role
Pangratz joins Activaero from Nektar Therapeutics, in San Francisco, US, where he recently served as executive director of business development. He brings to Activaero 20 years of life science experience.
Pangratz will join the Activaero management team and lead all business development, marketing and alliance management activities. He replaces Henrik Luessen, who has decided to focus on his own consultancy firm, but will continue to support Activaero’s business development team on a part-time basis.
You may also like
Cell & Gene Therapy
iOrganBio launches with $2m seed round and unveils CellForge, the first AI-powered cell manufacturing platform
Founded by experts in stem cell biology, organoid systems and biomedical engineering, the company aims to revolutionise how human cells are designed and produced for drug discovery and regenerative medicine
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Pharma 5.0
Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption
Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster